The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Dylan J Martini
No Relationships to Disclose
 
Wanling Xie
Consulting or Advisory Role - Bayer
 
Amin Nassar
No Relationships to Disclose
 
Ziad Bakouny
No Relationships to Disclose
 
John A. Steinharter
No Relationships to Disclose
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Ronan Flippot
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Nieves M. Chanza
Honoraria - Bayer
Travel, Accommodations, Expenses - Pfizer
 
Xiao X. Wei
Honoraria - OncLive
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - Exelixis; Nektar; Sanofi
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst)
 
Toni K. Choueiri
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Lauren Christine Harshman
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; Exelixis; Genentech; KEW; Merck; Novartis; Pfizer; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bayer